Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

Article Abstract:

The Food and Drug Administration (FDA) required a study to measure the effectiveness of drotrecogin alfa (activated) (DrotAA) for adults who suffered from acute sepsis but with a low risk of death. Findings indicate that DrotAA should not be applied to patients with acute sepsis and low risk of death due to the lack of a beneficial treatment effect and with a high occurrence of severe bleeding complications.

United Kingdom, Product information, Testing, Dosage and administration, Drotrecogin alfa (Medication)

---

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

Article Abstract:

The Food and Drug Administration (FDA) required a study to measure the effectiveness of drotrecogin alfa (activated) (DrotAA) for adults who suffered from acute sepsis but with a low risk of death. Findings indicate that DrotAA should not be applied to patients with acute sepsis and low risk of death due to the lack of a beneficial treatment effect and with a high occurrence of severe bleeding complications.

United States. Food and Drug Administration

---

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

Article Abstract:

A study to examine the role of intensive insulin therapy in severe sepsis is conducted. Results conclude that use of intensive insulin therapy with critically ill patients having sepsis increases the risk of serious adverse effects related to hypoglycemia.

Patient outcomes, Insulin, Hypoglycemia, Clinical report

Similar abstracts:

• Abstracts: Pregnancy characteristics and maternal risk of breast cancer. Caloric restriction and incidence of breast cancer
• Abstracts: Does vaginal closure force differ in the supine and standing positions? Can women without visible pubococcygeal muscle in MR images still increase urethral closure pressures?
• Abstracts: Alcoholic parotid sialadenosis. An unusual pattern of dental damage with salivary gland aplasia. Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case
• Abstracts: Protective conditioning for acute graft-versus-host disease. Tolerance and chimerism after renal and hematopoietic-cell transplantation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.